As the consumer group splits away today, what will New GSK buy now?
What a difference one really good Phase III readout and a couple of late-stage buyouts can make.
GSK CEO Emma Walmsley has been trying, hard, to build some excitement around the pipeline. And with the recent positive outcome for their RSV vaccine, she’s finally earning some market respect on that score. And with the big consumer split today, with the birth of Haleon, you can expect plenty of buzz about the need for another M&A deal to position the company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.